Brady S Moffett

Summary

Publications

  1. doi request reprint Readmissions for warfarin-related bleeding in pediatric patients after hospital discharge
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, Texas 77030, USA
    Pediatr Blood Cancer 60:1503-6. 2013
  2. doi request reprint Analysis of vancomycin therapeutic drug monitoring trends at pediatric hospitals
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX 77030, USA
    Pediatr Infect Dis J 32:32-5. 2013
  3. doi request reprint Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Ann Pharmacother 46:1193-7. 2012
  4. doi request reprint Risk factors for elevated INR values during warfarin therapy in hospitalized pediatric patients
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Pediatr Blood Cancer 58:941-4. 2012
  5. doi request reprint Enteral potassium supplementation in a pediatric cardiac intensive care unit: evaluation of a practice change
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Pediatr Crit Care Med 12:552-4. 2011
  6. doi request reprint Risk factors for postoperative acute kidney injury in pediatric cardiac surgery patients receiving angiotensin-converting enzyme inhibitors
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Pediatr Crit Care Med 12:555-9. 2011
  7. doi request reprint Impact of pharmacotherapy on interstage outcomes in single ventricle infants
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX 77030, USA
    Congenit Heart Dis 6:286-93. 2011
  8. pmc Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children
    Brady S Moffett
    Texas Children s Hospital, Department of Pharmacy, 6621 Fannin Street, MC 2 2510, Houston, TX 77030, USA
    Clin J Am Soc Nephrol 6:856-63. 2011
  9. doi request reprint Heparin dosing in obese pediatric patients in the cardiac catheterization laboratory
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Ann Pharmacother 45:876-80. 2011
  10. doi request reprint Evaluation of weight-based dosing of unfractionated heparin in obese children
    Breann N Taylor
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    J Pediatr 163:150-3. 2013

Collaborators

Detail Information

Publications31

  1. doi request reprint Readmissions for warfarin-related bleeding in pediatric patients after hospital discharge
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, Texas 77030, USA
    Pediatr Blood Cancer 60:1503-6. 2013
    ..Therapy initiation can be difficult as doses to achieve therapeutic outcomes are being determined. Evaluation of readmission for bleeding in pediatric patients discharged on warfarin therapy may be useful to prevent adverse events...
  2. doi request reprint Analysis of vancomycin therapeutic drug monitoring trends at pediatric hospitals
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX 77030, USA
    Pediatr Infect Dis J 32:32-5. 2013
    ..Vancomycin use in children has unique challenges, and consensus guidelines are lacking. We evaluated trends in vancomycin monitoring in children and estimated the impact of adult guidelines on patterns of vancomycin use...
  3. doi request reprint Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Ann Pharmacother 46:1193-7. 2012
    ..Many factors may alter gentamicin pharmacokinetics in this patient population and there are few data describing gentamicin dosing regimens in this patient population...
  4. doi request reprint Risk factors for elevated INR values during warfarin therapy in hospitalized pediatric patients
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Pediatr Blood Cancer 58:941-4. 2012
    ..By minimizing risk factors for elevated INR values patient morbidity may be minimized...
  5. doi request reprint Enteral potassium supplementation in a pediatric cardiac intensive care unit: evaluation of a practice change
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Pediatr Crit Care Med 12:552-4. 2011
    ..Although the enteral route is safer and thus may be a reasonable alternative, data on the efficacy of enteral potassium administration are lacking...
  6. doi request reprint Risk factors for postoperative acute kidney injury in pediatric cardiac surgery patients receiving angiotensin-converting enzyme inhibitors
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Pediatr Crit Care Med 12:555-9. 2011
    ..Risk factors for acute kidney injury after angiotensin-converting enzyme inhibitor initiation have yet to be defined in postoperative pediatric cardiac patients...
  7. doi request reprint Impact of pharmacotherapy on interstage outcomes in single ventricle infants
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX 77030, USA
    Congenit Heart Dis 6:286-93. 2011
    ..To characterize the pharmacotherapeutic regimens used in infants with single ventricle heart disease and determine the influence of outpatient medications on interstage weight gain...
  8. pmc Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children
    Brady S Moffett
    Texas Children s Hospital, Department of Pharmacy, 6621 Fannin Street, MC 2 2510, Houston, TX 77030, USA
    Clin J Am Soc Nephrol 6:856-63. 2011
    ..The cases were patients who developed AKI, as defined by the pediatric modified RIFLE (pRIFLE) criteria; patients without AKI served as controls and were matched by age category, gender, and disease state...
  9. doi request reprint Heparin dosing in obese pediatric patients in the cardiac catheterization laboratory
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Ann Pharmacother 45:876-80. 2011
    ..Unfractionated heparin (UFH) dosing may need to be adjusted when used in obese patients. The prevalence of pediatric obesity is increasing and, to our knowledge, no data exist to determine the effect of obesity on UFH therapy in children...
  10. doi request reprint Evaluation of weight-based dosing of unfractionated heparin in obese children
    Breann N Taylor
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    J Pediatr 163:150-3. 2013
    ..Secondary measures included UFH doses associated with therapeutic anticoagulation...
  11. doi request reprint Renal effects of fenoldopam in critically ill pediatric patients: A retrospective review
    Brady S Moffett
    Texas Children s Hospital, Department of Pharmacy, Houston, TX, USA
    Pediatr Crit Care Med 9:403-6. 2008
    ..We assessed the effects of fenoldopam on urine output and potential deleterious changes in hemodynamics or serum creatinine in children...
  12. doi request reprint Warfarin anticoagulation after congenital heart surgery at a large children's hospital
    Adam W Lowry
    Department of Pediatrics, Lillie Frank Abercrombie Section of Pediatric Cardiology, Baylor College of Medicine, Houston, TX, 77030, USA
    Pediatr Cardiol 33:1377-82. 2012
    ..The median time required to reach an INR of 2 after loading with warfarin was 2 days, and adverse events were uncommon...
  13. pmc Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients
    Mousumi Moulik
    Department of Pediatrics Cardiology, University of Texas Health Sciences Center, Houston, TX, USA
    J Am Coll Cardiol 56:582-92. 2010
    ..This study sought to evaluate the outcome and prevalence of viral endomyocardial infection after cardiac transplantation...
  14. doi request reprint Vancomycin dosing in obese pediatric patients
    Brady S Moffett
    Texas Children s Hospital, Houston, TX, USA
    Clin Pediatr (Phila) 50:442-6. 2011
    ..Data are lacking to guide antimicrobial dosing for overweight children. The authors hypothesized that obese children would have increased vancomycin serum trough concentrations compared with nonobese children...
  15. doi request reprint Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin
    Ashley A Richard
    Department of Pharmacy, Texas Children s Hospital, Houston, TX 77030, USA
    J Pediatr 162:293-6. 2013
    ..To determine if using actual body weight to dose enoxaparin in obese pediatric patients results in higher anti-Xa levels compared with non-obese pediatric patients...
  16. doi request reprint Altered gentamicin serum concentrations in obese pediatric patients
    Jamie J Choi
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, USA
    Pediatr Infect Dis J 30:347-9. 2011
    ..Obese pediatric patients had significantly higher gentamicin serum peak and trough concentrations despite receiving significantly lower mg/kg of actual body weight doses of gentamicin...
  17. doi request reprint Gentamicin dosing for pediatric patients with congenital heart disease
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, 6621 Fannin Street, MC 2 2510, Houston, TX 77030, USA
    Pediatr Cardiol 31:761-5. 2010
    ..Pediatric patients with congenital heart disease may require alterations in gentamicin dosing. Close pharmacokinetic monitoring of aminoglycoside therapy for these patients is warranted to ensure attainment of goal concentrations...
  18. doi request reprint Infectious complications and outcomes in children supported with left ventricular assist devices
    Antonio G Cabrera
    Department of Pediatrics, Section of Pediatric Cardiology, Baylor College of Medicine and Texas Children s Hospital, Houston, Texas 77030, USA
    J Heart Lung Transplant 32:518-24. 2013
    ..The aim of this study was to determine the incidence of infection among pediatric VAD recipients and to characterize the microbiology, associated risk factors, and clinical outcome...
  19. doi request reprint Once-daily gentamicin dosing in pediatric patients without cystic fibrosis
    Erin J McDade
    Department of Pharmacy, Texas Children s Hospital, Houston, Texas 77030, USA
    Pharmacotherapy 30:248-53. 2010
    ..To estimate an appropriate once-daily gentamicin dose and dosing interval for non-critical care pediatric patients older than 3 months of age without cystic fibrosis...
  20. ncbi request reprint Safety and efficacy of nesiritide in pediatric heart failure
    John L Jefferies
    Division of Pediatric Cardiology, Texas Children s Hospital, Houston, Texas 77030, USA
    J Card Fail 13:541-8. 2007
    ..We hypothesized that recombinant B-type natriuretic peptide (BNP) (nesiritide) could improve urine output and neurohormonal markers of heart failure without worsening renal function in pediatric patients...
  21. doi request reprint Perioperative atrial tachycardia is associated with increased mortality in infants undergoing cardiac surgery
    Pirouz Shamszad
    Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, and Department of Pharmacy, Texas Children s Hospital, Houston, TX 77030, USA
    J Thorac Cardiovasc Surg 144:396-401. 2012
    ..We hypothesized that atrial tachycardia in infants undergoing cardiac surgery is not rare and is associated with increased morbidity and mortality...
  22. ncbi request reprint Medication dosing and renal insufficiency in a pediatric cardiac intensive care unit: impact of pharmacist consultation
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, 6621 Fannin, St MC 2 2510, Houston, TX, 77030, USA
    Pediatr Cardiol 29:744-8. 2008
    ..Pharmacist consultation can result in improved dosing of medications and cost savings. The youngest patients are most at risk for inappropriate dosing...
  23. doi request reprint Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children
    Christopher A Thomas
    Department of Pharmacy, Texas Children s Hospital, Houston, Texas, USA
    Pediatr Crit Care Med 12:28-32. 2011
    ..To determine the efficacy and safety of labetalol for hypertensive crisis in children ≤ 24 months of age...
  24. doi request reprint Sodium-nitroprusside-induced cyanide toxicity in pediatric patients
    Christopher Thomas
    Texas Children s Hospital, Department of Pharmacy, 6621 Fannin Street, MC 2 2510, Houston, TX 77030, USA
    Expert Opin Drug Saf 8:599-602. 2009
    ..Conclusions: Sodium nitroprusside seems to be safe when used in critically ill pediatric patients. Cyanide toxicity may occur in patients with specific risk factors. Routine monitoring of cyanide levels may not be warranted...
  25. doi request reprint Impact of dexmedetomidine on early extubation in pediatric cardiac surgical patients
    Kimberly N Le
    Department of Pharmacy, Texas Children s Hospital, Houston, TX, 77030, USA
    Intensive Care Med 37:686-90. 2011
    ..To evaluate the impact of dexmedetomidine on early extubation in post-operative pediatric cardiac patients compared to patients on standard sedation regimens without dexmedetomidine...
  26. ncbi request reprint Safety of ketorolac in neonates and infants after cardiac surgery
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX 77030, USA
    Paediatr Anaesth 16:424-8. 2006
    ..There is a paucity of literature documenting the safety of using ketorolac in neonates and infants after cardiac surgery...
  27. doi request reprint High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias
    Jarrod D Knudson
    Department of Pediatric Cardiology, Baylor College of Medicine Texas Children s Hospital, 6621 Fannin St, MC 19345 C, Houston, TX 77030, USA
    Pediatr Cardiol 32:896-903. 2011
    ..No patients experienced significant QTc prolongation or proarrhythmia. Mean duration of follow-up was 3.3 ± 0.24 years. High-dose sotalol allows for safe and rapid control of refractory tachyarrhythmias in this young age group...
  28. ncbi request reprint Acetazolamide therapy for hypochloremic metabolic alkalosis in pediatric patients with heart disease
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, TX 77030, USA
    Am J Ther 14:331-5. 2007
    ..There are no data in children regarding the efficacy and safety of acetazolamide to treat hypochloremic metabolic alkalosis...
  29. doi request reprint Successful use of bivalirudin for superior vena cava recanalization and stent placement in a child with heparin-induced thrombocytopenia
    John P Breinholt
    Department of Pediatric Cardiology, Texas Children s Hospital, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA
    Pediatr Cardiol 29:804-7. 2008
    ..We present the case of a 2-year-old boy with HIT Type II who underwent recanalization of an occluded superior vena cava and stent placement, utilizing bivalirudin as anticoagulant...
  30. ncbi request reprint Future pharmacologic agents for treatment of heart failure in children
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, 6621 Fannin Street, MC 2 2510, Houston, TX 77030, USA
    Pediatr Cardiol 27:533-51. 2006
    ..The education and skill of the practitioner when applying these agents in pediatric heart failure is of utmost importance...
  31. ncbi request reprint Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment
    Brady S Moffett
    Department of Pharmacy, Texas Children s Hospital, Houston, Texas 77030
    Pharmacotherapy 26:1687-93. 2006
    ..To evaluate dosing and pharmacokinetic parameters of intravenous continuous-infusion procainamide in neonates, and to identify dosage regimens and factors leading to therapeutic procainamide levels and minimal adverse events...